Elutia (ELUT) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elutia (ELUT) has outperformed MiNK Therapeutics (INKT) over the past year, gaining 52.6% versus a loss of 24.1%. Over five years, ELUT leads with a -82.8% price change compared with -96.0% for INKT. MiNK Therapeutics is the larger company by market cap ($41.2 million vs $40.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | INKT |
|---|---|---|
| Share price | $0.9001 | $8.02 |
| Market cap | $39.96M | $41.17M |
| 1-day change | +11.12% | -6.85% |
| YTD return | +29.88% | -28.07% |
| 1-year return | +52.56% | -24.05% |
| 5-year return | -82.76% | -95.99% |
| EPS (TTM) | $-0.68 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.29M | — |
| Revenue growth (YoY) | -15.03% | — |
| Net income (latest FY) | $53.38M | $-12.49M |
| Gross margin | 53.66% | — |
| Operating margin | -218.91% | — |
| Net margin | 434.23% | — |
| 52-week high | $1.39 | $16.93 |
| 52-week low | $0.50 | $7.76 |
| Distance from 52-week high | -35.01% | -52.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +455.49% | +386.28% |
| Average volume | 185.17K | 15.74K |
| Shares outstanding | 44.40M | 5.13M |
| Employees | 25 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed INKT by 76.6 percentage points over the past year.
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
ELUT vs INKT FAQ
Which is bigger, Elutia or MiNK Therapeutics?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $41.17M compared with $39.96M for Elutia (ELUT).
Which stock has performed better over the past year, ELUT or INKT?
ELUT returned +52.56% over the past 12 months, compared with -24.05% for INKT (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.